A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin

A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin

Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium–glucose co-transporter 2 (SGLT2) inhibitors improve hyperglycemia, and the usefulness of co-administration of DPP-4 inhibitors and insulin therapy has been well established. However, it has been still uncertain whether combinat...

Full description

Bibliographic Details
Main Authors: Hiroshi Nomoto, Hideaki Miyoshi, Hajime Sugawara, Kota Ono, Shingo Yanagiya, Mayuko Oita, Akinobu Nakamura, Tatsuya Atsumi
Format: Article
Language:English
Published: BMC 2017-07-01
Series:Diabetology & Metabolic Syndrome
Subjects:
Blood glucose fluctuation
Dipeptidyl peptidase-4 inhibitors
Sodium–glucose co-transporter 2 inhibitors
Type 2 diabetes mellitus
Online Access:http://link.springer.com/article/10.1186/s13098-017-0255-8

Internet

http://link.springer.com/article/10.1186/s13098-017-0255-8

Similar Items